Acrivon Therapeutics, Inc. Common Stock (ACRV) Price/OCF Ratio: History & Chart

Acrivon Therapeutics, Inc. Common Stock(ACRV)

Biotechnology · Watertown, MA

$1.94-0.04 (-2.02%)

Delayed quote: Oct 6, 2026, 11:54 AM EDT

About Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.

Watertown, MA

75 employees

www.acrivon.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Peter Blume-Jensen

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Acrivon Therapeutics, Inc. Common Stock (ACRV)	$83.04M	N/A	N/A	N/A	N/A
MediciNova, Inc. (MNOV)vs ›	$82.73M	N/A	111.15	111.15	111.15
LENSAR Inc (LNSR)vs ›	$82.53M	N/A	N/A	N/A	N/A
Citius Oncology, Inc. (CTOR)vs ›	$83.48M	N/A	786.57	786.57	786.57
Cognition Therapeutics, Inc. (CGTX)vs ›	$85.01M	N/A	N/A	N/A	N/A
Humacyte, Inc. (HUMA)vs ›	$85.13M	N/A	N/A	N/A	N/A
Cardiff Oncology, Inc. (CRDF)vs ›	$84.78M	N/A	17.74	16.00	17.53
ProMIS Neurosciences, Inc. (PMN)vs ›	$84.57M	N/A	N/A	N/A	N/A
Nutriband Inc. (NTRB)vs ›	$81.45M	N/A	N/A	N/A	N/A
Atara Biotherapeutics, Inc. (ATRA)vs ›	$86.06M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

Acrivon Therapeutics, Inc. Common Stock (ACRV)

$83.04M

N/A

MediciNova, Inc. (MNOV)vs ›

$82.73M

N/A

111.15

LENSAR Inc (LNSR)vs ›

$82.53M

N/A

Citius Oncology, Inc. (CTOR)vs ›

$83.48M

N/A

786.57

Cognition Therapeutics, Inc. (CGTX)vs ›

$85.01M

N/A

Humacyte, Inc. (HUMA)vs ›

$85.13M

N/A

Cardiff Oncology, Inc. (CRDF)vs ›

$84.78M

N/A

17.74

16.00

17.53

ProMIS Neurosciences, Inc. (PMN)vs ›

$84.57M

N/A

Nutriband Inc. (NTRB)vs ›

$81.45M

N/A

Atara Biotherapeutics, Inc. (ATRA)vs ›

$86.06M

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

ACRV Price/OCF Ratio Metrics

ACRV Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics